Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)

JAKL, Martin, Pavel CERVINKA, Jan KAŇOVSKÝ, Petr KALA, Martin POLOCZEK, Michaela CERVINKOVA, Hiram G BEZERRA, Zdenek VALENTA a Marco Aurelio COSTA. Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial). CARDIOLOGY JOURNAL. GDANSK: VIA MEDICA, 2023, roč. 30, č. 6, s. 921-928. ISSN 1897-5593. Dostupné z: https://dx.doi.org/10.5603/CJ.a2023.0013.

Základní údaje

• Originální název: Randomized comparison of 9-month stent strut coverage of biolimus and everolimus drug-eluting stents assessed by optical coherence tomography in patients with ST-segment elevation myocardial infarction. Long-term (5-years) clinical follow-up (ROBUST trial)
• Autoři: JAKL, Martin (203 Česká republika), Pavel CERVINKA (203 Česká republika, garant), Jan KAŇOVSKÝ (203 Česká republika, domácí), Petr KALA (203 Česká republika), Martin POLOCZEK (203 Česká republika), Michaela CERVINKOVA (203 Česká republika), Hiram G BEZERRA, Zdenek VALENTA (203 Česká republika) a Marco Aurelio COSTA.
• Vydání: CARDIOLOGY JOURNAL, GDANSK, VIA MEDICA, 2023, 1897-5593.

Další údaje

• Originální jazyk: angličtina
• Typ výsledku: Článek v odborném periodiku
• Obor: 30201 Cardiac and Cardiovascular systems
• Stát vydavatele: Polsko
• Utajení: není předmětem státního či obchodního tajemství
• WWW: URL
• Impakt faktor: Impact factor: 2.900 v roce 2022
• Kód RIV: RIV/00216224:14110/23:00133406
• Organizační jednotka: Lékařská fakulta
• Doi: http://dx.doi.org/10.5603/CJ.a2023.0013
• UT WoS: 001116942600001
• Klíčová slova anglicky: drug-eluting stent; primary percutaneous coronary intervention; stent strut coverage; optical coherence tomography; ST-segment elevation myocardial infarction; clinical trials
• Štítky: 14110211, rivok
• Příznaky: Mezinárodní význam, Recenzováno

Anotace

Background: The aim of the study was to compare healing (assessed by optical coherence tomography [OCT]) of biolimus A9 (BES) and everolimus drug-eluting stents (EES) at 9-month follow-up in patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI). Nine-month clinical and angiographic data were also compared in both groups as well as clinical data at 5 years of follow-up.Methods: A total of 201 patients with STEMI were enrolled in the study and randomized either to pPCI with BES or EES implantation. All patients were scheduled for 9 months of angiographic and OCT follow-up.Results: The rate of major adverse cardiovascular events (MACE) was comparable at 9 months in both groups (5% in BES vs. 6% in the EES group; p = 0.87). Angiographic data were also comparable between both groups. The main finding at 9-month OCT analysis was the greatly reduced extent of mean neointimal area at the cost of a higher proportion of uncovered struts in the BES group (1.3 mm2 vs. 0.9 mm2; p = 0.0001 and 15.9% vs. 7.0%; p = 0.0001, respectively). At 5 years of clinical follow-up the rate of MACE was comparable between both groups (16.8% vs. 14.0%, p = 0.74).Conclusions: The study demonstrates a very low rate of MACE and good 9-month stent strut coverage of second-generation BES and EES in patients with STEMI. BES showed greatly reduced extent of mean neointimal hyperplasia area at the cost of a higher proportion of uncovered struts when compared to EES. The rate of MACE was low and comparable in both groups at 5 years. (Cardiol J 2023; 30, 6: 921-928)